Drugs / PM1021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05537051 | Oct 2023 → Oct 2024 | cancer | BioNTech SE | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM1021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05537051 ↗ |
| Action | Inhibit | “PM1021 (Anti-TIGIT)” NCT05537051 ↗ |
| Modality | Monoclonal antibody | “PM1021, a monoclonal anti-T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) antibody (IgG1)” NCT05537051 ↗ |